Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Carcinoma, Papillary
  • Deoxycytidine
  • Thyroid Neoplasms

abstract

  • We conclude that the majority of differentiated thyroid cancers (74%) express TP and low levels of TS (63% undetectable). The results support the hypothesis that capecitabine is activated in the majority of differentiated thyroid cancers and that 32% have favorable expression of all three enzymes (TP, TS, and DPD).

publication date

  • May 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-003-0732-7

PubMed ID

  • 15132128

Additional Document Info

start page

  • 409

end page

  • 14

volume

  • 53

number

  • 5